Analyzing breath to diagnose infections in hematology patients
Exhaled Breath Analysis for Rapid Diagnosis in Opportunistic Respiratory Infections in Hematological Patients
Universitaire Ziekenhuizen KU Leuven · NCT03299608
This study is testing whether analyzing breath samples can help doctors find respiratory infections earlier in patients with blood diseases who are receiving intensive chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 246 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitaire Ziekenhuizen KU Leuven (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Leuven) |
| Trial ID | NCT03299608 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the diagnostic, prognostic, and therapeutic value of spectrometric analysis of exhaled breath in patients with hematological diseases who are undergoing intensive chemotherapy. By analyzing breath samples, researchers hope to identify respiratory tract infections more effectively in this vulnerable population. The study will include patients with specific hematological conditions, and it will focus on the correlation between breath analysis results and clinical outcomes. The observational nature of the study allows for real-time data collection without altering patient treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with specific hematological conditions receiving intensive chemotherapy.
Not a fit: Patients with active respiratory infections or those with hematological diseases outside the specified criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to quicker and more accurate diagnoses of respiratory infections in hematology patients, improving patient management and outcomes.
How similar studies have performed: While breath analysis for diagnostic purposes is an emerging field, this specific approach in hematology patients is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18y at start of study * One of the following diagnoses: * De novo, refractory or relapsed AML/MDS receiving intensive chemotherapy * De novo, refractory or relapsed ALL/T-lymphoblastic lymphoma receiving intensive chemotherapy * Aplastic anemia requiring ATG therapy * Any patient admitted for either autologous hematopoietic stem cell transplantation. Transplantation may not have been performed at time of enrolment. * Any patient admitted with allogeneic hematopoietic stem cell transplantation within the last year, or planned during this admission. * Written informed consent obtained from the patient Exclusion Criteria: * Hematological disease beyond the specified inclusion criteria * Signs of active respiratory infection * If previously enrolled: incomplete clearance of all signs of respiratory infection (both clinically, microbiologically and radiologically).
Where this trial is running
Leuven
- University Hospitals Leuven — Leuven, Belgium (RECRUITING)
Study contacts
- Study coordinator: Toine Mercier, MD
- Email: toine.mercier@uzleuven.be
- Phone: +32 16 34 00 04
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Respiratory Tract Infections, Hematologic Diseases